Table 3.

Summary of multivariate analysis of outcome in lung adenocarcinoma patients by expression of EZH2 and TTF-1

FeaturesCategoriesP valueHR (95% CI)Overall Pa
Overall survival
 EZH2Median (score 41.7)0.00021.962 (1.383–2.782)
 TTF-1Median (score 150.0)0.00610.613 (0.433–0.870)
 AgeMedian (66.3 years)<0.00012.347 (1.644–3.351)
 SexMale vs. Female0.08201.348 (0.963–1.887)
 Tumor sizeMedian (2.7 cm)0.03011.467 (1.038–2.075)
 TNM stageIII vs. I<0.00013.282 (1.987–5420)<0.0001
II vs. I0.03791.537 (1.024–2.308)
 Adjuvant therapyYes vs. No0.01690.583 (0.375–0.908)
Recurrence-free survival
 EZH2Median (score 41.7)0.02491.542 (1.056–2.245)
 TTF-1Median (score 150.0)0.22890.793 (0.543–1.157)
 Tumor sizeMedian (2.7 cm)0.04451.478 (1.01–2.164)
 TNM stageIII vs. I<0.00014.647 (2.746–7.863)<0.0001
II vs. I0.00212.022 (1.29–3.17)
 Adjuvant therapyYes vs. No0.28850.789 (0.509–1.222)
  • aP value for overall effect.